Abstract. The incidence of gastric cancer (GC) is extremely high in East Asia. GC is also one of the most common and lethal forms of cancer from a global perspective. However, to date, we have not been able to determine one or several genes as biomarkers in the diagnosis of GC and have also been unable to identify the genes which are important in the therapy of GC. In this study, we analyzed all genome-wide expression profiling arrays uploaded onto the Gene Expression Omnibus (GEO) database to filtrate the differentially expressed genes (DEGs) between normal stomach tissues and GC tissues. GSE13911, GSE19826 and GSE79973 were based on the GPL570 platform, and GSE29272 was based on the GPL96 platform. We screened out the DEGs from the two platforms and by selecting the intersection of these two platforms, we identified the common DEGs in the sequencing data from different laboratories. Finally, we obtained 3 upregulated and 34 downregulated DEGs in GC from 384 samples. As the number of downregulated DEGs was greater than that of the upregulated DEGs, functional analysis and pathway enrichment analysis were performed on the downregulated DEGs. Through our analysis, we identified the most significant genes associated with GC, such as secreted phosphoprotein 1 (SPP1), sulfatase 1 (SULF1), thrombospondin 2 (THBS2), ATPase H + /K + transporting beta subunit (ATP4B), gastric intrinsic factor (GIF) and gastrokine 1 (GKN1). The prognostic power of these genes was corroborated in the Oncomine database and by Kaplan-Meier plotter (KM-plotter) analysis. Moreover, gastric acid secretion, collecting duct acid secretion, nitrogen metabolism and drug metabolism were significantly related to GC. Thus, these genes and pathways may be potential targets for improving the diagnosis and clinical effects in patients with GC.
Introduction
Gastric cancer (GC) is the third leading cause of cancerrelated mortality in both sexes worldwide (723,000 deaths, 8 .8% of the total). The highest estimated mortality rates are in Eastern Asia, and the lowest in Northern America (1) . The GSE series that we finally screened out included 315 samples from China and only 69 samples from Italy, indicating the high incidence of GC in Asian countries. The cause of death in patients with GC is mostly due to late diagnosis, rapid metastatic spread and the limited effectiveness of available therapeutics (2) . As regards the diagnosis of GC, histopathological diagnosis remains the gold standard thus far; however, contrast-enhanced ultrasound is useful in the differential diagnosis of gastric subepithelial lesions and can guide further management and follow-up (3) (4) (5) . Nevertheless, the identification of one or several genes as biomarkers for application in the non-invasive tumor molecular diagnosis of GC, and the better understanding of GC pathogenesis is essential for the establishment of diagnostic markers, as well as novel therapeutic methods. In the treatment of GC, surgery alone is often not very effective (6) , even in patients with relatively early stages of the disease. In an attempt to reduce systemic recurrence following surgery alone, adjuvant chemotherapy has been used in trials (7) ; however, the effects are still limited (8) . We thus are eager to establish more effective diagnostic and treatment strategies by examining GC at the genetic level. As the pathogenesis of GC involves the dysfunction of molecular signaling pathways, many efforts have been undertaken in recent years to emphasize the molecular heterogeneity responsible for the process of carcinogenesis (9, 10) . Currently, some of these aberrant molecular signaling pathways are utilized as targets of interventions with novel therapeutic agents, some of which are already used in the treatment of GC, while others remain in the phase of clinical trials (11) . In this study, through our results of data analysis, we aimed to shed light on the identification of potential diagnostic and therapeutic markers for GC.
The high-throughput platforms for the analysis of gene expression, such as expression profiling microarrays (12) , are increasingly valued as promising tools in medical oncology with great clinical applications (13) (14) (15) . During the analysis of whole genome sequencing results from different laboratories, the statistical power is increased and the predictive power is more accurate; moreover, the bias of individual studies can be overcome. The aim of this study was to identify potential significant biomarkers for the diagnosis and treatment of GC. For this purpose, we analyzed the genomic signature of human GC.
In the present study, we downloaded the original data (GSE13911, GSE19826, GSE79973 and GSE29272) from Gene Expression Omnibus (GEO), which is a database repository which archives and serves as a hub for microarray data deposit and retrieval (16) . Subsequently, the differentially expressed genes (DEGs) were screened using R language. To better clarify the pathological mechanisms, we performed functional analysis and pathway enrichment analysis, such as Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis for common DEGs screened from the 4 datasets (17) . We hope that our findings will provide further insight into gastric carcinogenesis at the molecular level and may aid in the identification of novel potential candidate biomarkers for diagnosis, prognosis and drug targets in GC.
Materials and methods
Microarray data preprocessing. The microarray gene expression data were derived from searches using 'astric cancer array' and 'human [organism]' and 'expression profiling by array [dataset type]' as the keywords in the GEO database of the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/). There are 135 results under this search condition. Among these, there are 4 types of expression profiling arrays, including genome-wide expression profiling, exon-level expression profiling, cDNA chip and oligonucleotide microarray, which contain 23 GEO series comparing differences between normal stomach tissues and GC tissues. The classification and summary of the GEO series are presented in Table I .
We conducted genome-wide analysis of gene expression between normal stomach tissues and GC tissues shown as the first row in Table I . Four independent datasets from 2 platforms were used for analysis, which are introduced in Table II . Three of these (GSE13911, GSE19826 and GSE79973) were based on the GPL570 platform, which tested the expression values of 21,755 genes. Thus, we merged the gene expression data of 116 patients from the 3 datasets based on the gene symbol to perform further analysis. A 4th dataset, GSE29272, based on the GPL96 platform was analyzed separately; it tested the expression values of 13,102 genes. The process of data filing is shown in Fig. 1 .
Data preprocessing prior to difference analysis. We utilized the robust multi-array average algorithm of the affy package in R language to convert the raw data of 4 CEL files into expression data. The expression levels of the probe sets were converted into gene expression levels by the Bioconductor annotation function of R language according to different platforms. The expression values of multiple probes for a given gene were averaged. With this, we obtained 4 tables containing the expression values of different genes in different patients based on the 4 GEO series. The function termed SameGene in R language was then used to merge the gene expression data of 116 patients from the GSE13911, GSE19826 and GSE79973 datasets according to the gene symbol as 1 table. In addition, we now had 2 tables, one from the GSE13911, GSE19826 and GSE79973 datasets, and another from the GSE29272 dataset. Batch normalization was conducted on all expression profiling data using ComBat algorithm in Surrogate Variable Analysis package of R language. The normalization can eliminate the systematic variations among studies.
Screening of DEGs.
The candidate genes of GC tumors and normal stomach tissues were analyzed using the linear models for microarray data (Limma) package in Bioconductor (http:// www.bioconductor.org/packages/release/bioc/html/limma.html). Results with a |log 2 fold change| (|log 2 FC|) >2 and an adjusted P-value <0.05 were considered significant.
GO and KEGG pathway enrichment analysis for DEGs.
The Database for Annotation, Visualization and Integrated Discovery (DAVID, http://david.abcc.ncifcrf.gov/) is characterized by functional annotation and biological interpretation for genome-scale datasets, which improve an integrated and high throughput data mining environment. To evaluate the involvement of DEGs in functional and metabolic pathways, DAVID was utilized to perform GO and KEGG enrichment analysis for downregulated DEGs (following the intersection of the DEGs screened from 2 sequencing platforms) with a P-value <0.05 as a strict cut-off. The aim of GO (http://www.geneontology.org/) Oncomine database analysis and Kaplan-Meier plotter analysis for DEGs. The expression levels of the common DEGs obtained from the 2 sequencing platforms in GC were analyzed using the Oncomine Cancer Profiling Database (https://www. oncomine.org) (18, 19) . The mRNA expression fold in cancer tissue compared to normal tissue was obtained and compared.
For survival analyses, the prognostic value of the selected DEGs in GC were analyzed using Kaplan-Meier Plotter (http://kmplot.com/analysis/) and tested for significance using log-rank tests (20, 21) . The analysis was performed according to the manufacturer's instructions [http://kmplot.com/analysis/index.php?p (21)]. The vertical axis stands for gene expression values. The black horizontal line represents the median of expression value of the sample, which is almost on a straight line after batch normalization, suggesting that normalized data were qualified.
Results

Normalization of gene expression values.
Selection of DEGs.
We used R Limma package software to analyze which gene sets were deregulated in both comparisons with the threshold of |log 2 FC| >2 and P<0.05. The DEGs were identified using the t-test statistical algorithm. The significant genes lists were selected according to their fold changes in expression values.
In the first group of data that contained 3 GEO series from GPL570 (116 samples), a total of 224 DEGs between 60 GC samples and 56 normal controls were screened, which included 59 upregulated genes and 165 downregulated genes. The number of downregulated genes was higher than that of upregulated genes. In Table III , we list the first 40 genes with the most obvious fold changes in expression values. A heatmap of hierarchical clustering of the top 50 screened DEGs was drawn according to the P-value (Fig. 3A) . Fig. 3B shows a volcano plot of gene expression differences between the GC tissues and controls. The y-axis in the volcano plot represents the distributions of fold change [(log 2 (fold change)] and the x-axis resprents the P-values [-log 10 (P-value)].
In another group of data that contained 1 GEO series from GPL96 (268 samples), a total of 37 DEGs between 134 GC samples and 134 normal controls were screened, which included 7 upregulated genes and 35 downregulated genes. All these are listed in Table IV . A heatmap of hierarchical clustering of all the screened DEGs was drawn according to the P-value (Fig. 4A) . Fig. 4B depicts the volcano plot of gene expression differences between the GC tissues and controls. The y-axis in the volcano plot represents the distributions of fold change [(log 2 (fold change)] and the x-axis represents the P-values [-log 10 (P-value)] (Fig. 4B) . The top 40 DEGs, either up-or downregulated DEGS, screened between the normal stomach tissues and GC tissues from the different sequencing platforms are shown in Tables III and IV, respectively. We then wished to identify the common DEGs that were screened out from the different sequencing platforms. Using the Venn diagram (http://bioinfogp.cnb.csic.es/tools/venny/), we found the intersection of the DEGs screened from two sequencing platforms; there were 3 upregulated DEGs ( Fig. 4C and Table V ) and 34 downregulated DEGs (Fig. 4C and Table VI) in GC. The number of downregulated DEGs was higher than that of upregulated DEGs.
GO analysis and KEGG pathway analysis of screened
DEGs. Following the intersection of the DEGs which were screened out from the two sequencing platforms, the number of downregulated DEGs were greater than that of upregulated DEGs. Thus, function analyses were performed on the downregulated DEGs. For the downregulated DEGs, the enriched functions in the BP category were enriched in the digestion process, cellular aldehyde metabolic process, oxidation-reduction process, potassium ion import and so on (Table VII) . To better clarify the pathological mechanisms, we performed KEGG enrichment analysis. According to the results of KEGG pathway enrichment analysis, the downregulated genes were significantly enriched in gastric acid secretion (P=8.8E-7), collecting duct acid secretion (P=2.2E-3) and nitrogen metabolism (P=4.3E-2) (Table VIII) .
Overall survival (OS) analysis of common DEGs.
To clarify whether the expression value of the common DEGs correlated with cancer progression, we first analyzed the expression levels of the common DEGs with the cancer microarray database, Oncomine. There were 37 common DEGs screened from two sequencing platforms, 3 upregulated DEGs and 34 downregulated DEGs. We selected 3 downregulated DEGs which had most There are 59 upregulated genes (log 2 fold change >2) and 40 with the greatest changes in expression are listed. There are also 165 downregulated genes (|log 2 fold change| >2) and 40 with the greatest changes in expression are listed. DEGs, differentially expressed genes.
evident fold changes in expression values and 3 common upregulated DEGs to be analyzed. The results revealed that common upregulated DEGs were significantly upregulated in GC tissues (P<0.05) (Fig. 5A) ; however, the downregulation of the 3 selected common downregulated DEGs in the GC tissues was not so evident (P>0.05) (Fig. 5B) . We then analyzed the expression of common DEGs using Kaplan-Meier plotter analysis. The results revealed that the high expression levels of 3 common upregulated DEGs were associated with a worse prognosis (P<0.01) (Fig. 5C) ; however, the association between the downregulated DEGs and OS was not so evident (P>0.05) (Fig. 5D) . The results of common DEGs expressed in the normal stomach and different types of GCs are consistent with predicted results based on GEO database in this study (Fig. 6) .
The results reminded us that perhaps in GC, the accumulated expression of certain oncogenes may play an important role in the induction of gastric carcinogenesis, such as the secreted phosphoprotein 1 (SPP1), sulfatase 1 (SULF1) and thrombospondin 2 (THBS2) genes.
Discussion
GC is a product of cumulative genetic, epigenetic, somatic and endocrine aberrations (22) . Understanding the molecular mechanisms of GC is of critical importance for diagnosis and treatment. Since high throughput sequencing (23, 24) can reveal the expression levels of thousands of genes in the human genome simultaneously, it has been widely used to predict the potential therapeutic targets for GC (25) . By taking into consideration the analysis of whole genome sequencing results from different laboratories, the statistical power can be increased and the prediction may be more accurate; moreover, the bias of individual studies can be overcome. In this study, the common DEGs that were screened out from different sequencing platforms containing 384 samples were listed. There were 3 common upregulated DEGs and 34 common downregulated DEGs in GC with the threshold of |log 2 FC| >2 and P<0.05. Among these, the expression values of ATPase H + /K + transporting beta subunit (ATP4B), gastrokine 1 (GKN1), gastric intrinsic factor (GIF), ATPase H + /K + transporting alpha subunit (ATP4A), lipase F, gastric type (LIPF) and pepsinogen 4, group I (pepsinogen A; PGA4) between the GC and normal tissues were altered by >2 4 fold, and independent of the platform, the fold change expression value of 6 genes was ranked in the top 6. Raja et al found that the downregulation of ATP4A and ATP4B involved DNA methylation and methylated ATP4B DNA in plasma was a potential biomarker for GC (26) ; to the best of our knowledge, this was the only study to date which investigated the association of ATP4B or ATP4A with GC and these findings were consistent with our analysis. GKN1 has convergent functions in terms of the modulation of gastric mucosal homeostasis and inflammation, activity in epithelial wound healing or repair, and anti-proliferative activity, and there has been relatively more research on this gene in gastric carcinogenesis (27) (28) (29) (30) . GIF is a gastric intrinsic factor and LIPF encodes gastric lipase; it is an enzyme involved in the digestion of dietary triglycerides in the gastrointestinal tract, and is responsible for 30% of fat digestion processes occurring in humans. PGA4 encodes a protein precursor of the digestive enzyme pepsin, a member of the peptidase A1 family of end peptidases. The functional deficiency of these genes can lead to GC (31, 32) . On the whole, it can be deduced that the DEGs we screened from GC tissues and normal stomach may aid in the investigation of GC and the discovery of novel drugs.
The GO term analysis revealed that the downregulated DEGs were mainly involved in the digestion process, cellular There are 7 upregulated genes (log 2 fold change >2) and all are listed. There are also 35 downregulated genes (|log 2 fold change| >2) and all are listed. DEGs, differentially expressed genes.
aldehyde metabolic process (33), oxidation-reduction process, potassium ion import and so on (34) . Furthermore, the enriched KEGG pathways of the downregulated DEGs included gastric acid secretion, collecting duct acid secretion and Nnitrogen metabolism. Di Mario and Goni reported that gastric acid secretion was strongly associated with GC (35) . Decreased or increased gastric acid secretion can lead to various diseases in the stomach, such as gastroesophageal reflux disease, chronic atrophic gastritis and others (36) . Some drugs based on acid secretion, namely the H 2 -receptor antagonists (H 2 RAs) and proton pump inhibitors (PPIs), allow for the effective and safe treatment of peptic ulcers and other acid-related disorders (37) .
The collecting duct is responsible for the final secretion or re-absorption of protons and bicarbonate, it mediates Na, K and water transport and intercalated cells (ICs), which are specialized for acid-base transport (38) . To date, to the best of our knowledge, there is no study available on collecting duct acid secretion and GC; however, acid-base balance is often clinically linked (39) . The association between collecting duct acid secretion and GC warrants further investigation. Studies have suggested that the implementation of effective nutritional support is crucial for improving the post-operative nutrient consumption and improving prognosis, as well as the quality of rehabilitation in patients with GC (40). Ishizuka et al (41) reported that the majority of patients with advanced-stage GC experienced nutritional deficiency, which, in combination with surgical trauma, can easily cause post-operative immune dysfunction and malnutrition, imposing a certain influence on recovery, and this has been validated by a number of studies (42, 43) . Functional analyses can help us to better understand the mechanisms of GC and may provide us with a guide to GC prevention and treatment. These pathways may be potential targets for improving the diagnosis and clinical effects in patients with GC. However, further molecular biological experiments are required to confirm the function of the identified genes in GC and further analyses of other aspects in gastric carcinogenesis, such as epigenetic modification and single-nucleotide polymorphism (SNP) mutations (44) are also required. However, this study provides information for researchers which may aid in the identification of possible candidate genes and pathways which may be involved in GC. We provide further insight of gastric carcinogenesis at the molecular level and information of potential candidate biomarkers for the diagnosis, prognosis and drug targets for GC.
In conclusion, the present study utilized the analysis of whole genome sequencing results from different laboratories, and screened out the common DEGs from different sequencing platforms containing 384 samples. There were 3 common upregulated DEGs and 34 common downregulated DEGs in GC with the threshold of |log 2 FC| >2 and P<0.05. Functional analysis revealed that the downregulated DEGs were mainly involved in the digestion process, cellular aldehyde metabolic process, oxidation-reduction process, potassium ion imports and so on. Furthermore, the enriched KEGG pathways of downregulated DEGs included gastric acid secretion, collecting duct acid secretion and nitrogen metabolism. Through the analysis of all GSE series comparing GC cancer tissues and control in the GEO database, the prediction is more accurate and the bias of individual studies can be overcome. We also examined the association between the prognosis values and the common DEGs screened from 4 laboratories, and found that the common upregulated DEGs may play an important role in the development of GC. (C) Kaplan-Meier plots of OS of patients with GC in whole datasets; patients with a high expression of upregulated DEGs exhibited a poor survival. Data were obtained from the Kaplan-Meier plotter database. The P-value was calculated by a log-rank test. (D) Kaplan-Meier plots of the OS of patients with GC in whole datasets; the association between the expression of downregulated DEGs and patient survival was not evident. Data were obtained from the Kaplan-Meier plotter database. The P-value was calculated by a log-rank test. 
